<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1901">
  <stage>Registered</stage>
  <submitdate>25/03/2008</submitdate>
  <approvaldate>25/03/2008</approvaldate>
  <nctid>NCT00645736</nctid>
  <trial_identification>
    <studytitle>CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study</studytitle>
    <scientifictitle>Study of Acquired Viral Mutations in Chronic Hepatitis B Patients on Antihepadnaviral Therapy</scientifictitle>
    <utrn />
    <trialacronym>CHARM</trialacronym>
    <secondaryid>GS-AU-103-0185</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - No intervention

1 - Single cohort


Other interventions: No intervention
No intervention

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Descriptive statistics for clinical and viral characteristics of the study population</outcome>
      <timepoint>Single timepoint (blood draw)</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Aged 18 years and over

          -  Provided informed consent

          -  Diagnosis of chronic hepatitis B (HBsAg documented for at least 6 months)

          -  Currently prescribed antihepadnaviral therapy (including, but not limited to:
             lamivudine, adefovir, entecavir, tenofovir or telbivudine) for chronic hepatitis B
             management

          -  Been taking current antihepadnaviral therapy for at least 6 months prior to
             recruitment

          -  Negative tests for HIV Ab, Hepatitis C Ab and Hepatitis D Ab within the previous 2
             years</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known or suspected co-infection with HIV, Hepatitis C or Hepatitis D

          -  Concomitant immunosuppression / immunomodulatory therapies

          -  Diagnosis of hepatocellular carcinoma where anticipated life expectancy is less than 6
             months

          -  Current participation in an interventional, blinded, pharmaceutical industry-sponsored
             clinical trial

          -  Current Child Pugh class C classification (current Child Pugh score &gt; 9)

          -  Other known or suspected cause of chronic liver disease

          -  Any other reason that, in the investigator's opinion, participation in the study would
             not be in the participant's best interest.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration>Cross-sectional</duration>
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>788</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Gilead Sciences Pty Ltd - East Melbourne</hospital>
    <postcode>3002 - East Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study has the aim of describing viral mutation profiles in patients diagnosed with
      chronic hepatitis B receiving antihepadnaviral therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00645736</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Howard Wraight</name>
      <address>Gilead Sciences Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>